The use of receiver operating characteristic analysis for detection of minimal residual disease using five-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse

Cytometry Part B - Clinical Cytometry

Volumn 76, Issue 2, 2009, Pages 91-101

  Al Mawali, Adhra ^a,b,c   Gillis, David ^a   Lewis, Ian ^a,b,c  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b HANSON INSTITUTE   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Acute myeloid leukemia; Leukemia associated phenotypes; Minimal residual disease; Multiparameter flow cytometry; Receiver operating characteristics

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW EXAMINATION; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; CELLULAR DISTRIBUTION; DISEASE CLASSIFICATION; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ANTINEOPLASTIC PROTOCOLS; BONE MARROW CELLS; CELL COUNT; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECURRENCE; RISK FACTORS; SIGNAL PROCESSING, COMPUTER-ASSISTED; SURVIVAL RATE; YOUNG ADULT;

EID: 66249099567     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20444     Document Type: Article

References (32)

1. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E III. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and leukemia Group B. N Engl J Med 1994;331:896-903.
2. Raanani P, Ben-Bassat I. Detection of minimal residual disease in acute myelogenous leukemia. Acta Haematol 2004;112:40-54.
3. Vidriales MB, San-Miguel JF, Orfao A, Coustan-Smith E, Campana D. Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol 2003;16:599-612.
4. Schmidt HH, Strehl S, Thaler D, Strunk D, Sill H, Linkesch W, Jager U, Sperr W, Greinix HT, Konig M, Emberger W, Haas OA. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: Breakpoint cluster region and clinical implications. Leukemia 2004;18:1115-1121.
5. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104:3078-3085.
6. Kern W, Danhauser-Riedl S, Ratei R, Schnittger S, Schoch C, Kolb HJ, Ludwig WD, Hiddemann W, Haferlach T. Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow. Haematologica 2003;88:646-653.
7. Al-Mawali AH, Gillis D, Hissaria P, Lewis ID. Incidence, sensitivity and specificity of leukaemia associated phenotypes in acute myeloid leukaemia patients using specific five-colour multiparameter flow cytometry. Am J Clin Pathol 2008;129:934-945.
8. Feller N, van der Pol MA, van Stijn A, Weijers GW, Westra AH, Evertse BW, Ossenkoppele GJ, Schuurhuis GJ. MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia. Leukemia 2004;18:1380-1390.
9. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, Ramos F, Calmuntia MJ, Perez JJ, Gonzalez M, Orfao A. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:1746-1751.
10. Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, Battaglia A, Catalano G, Del Moro B, Cudillo L, Postorino M, Masi M, Amadori S. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000;96:3948-3952.
11. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui CH, et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998;351:550-554.
12. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Pui CH, Pounds S, Andreansky M, Behm FG, Raimondi SC, Shurtleff SA, Downing JR, Campana D. Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol 2003;123:243-252.
13. Coustan-Smith E, Sancho J, Hancock ML, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Pui CH, Campana D. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood 2002;100: 2399-2402.
14. Ciudad J, San Miguel JF, Lopez-Berges MC, Vidriales B, Valverde B, Ocqueteau M, Mateos G, Caballero MD, Hernandez J, Moro MJ, Mateos MV, Orfao A. Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1998;16:3774-3781.
15. San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M, Caballero D, Garcia-Marcos MA, Ramos F, Fernandez-Calvo J, Calmuntia MJ, Diaz-Mediavilla J, Orfao A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90:2465-2470.
16. Venditti A, Maurillo L, Buccisano F, Tamburini A, Del Poeta G, Del Principe MI, Panetta P, Consalvo MI, Mazzone C, Tendas A, Trawinska M, Forte V, Amadori S. Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Leuk Lymphoma 2003;44:445-450.
17. Venditti A, Tamburini A, Buccisano F, Del Poeta G, Maurillo L, Panetta P, Scornajenghi KA, Cox C, Amadori S. Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia. J Hematother Stem Cell Res 2002;11:349-357.
18. Drach J, Drach D, Glassl H, Gattringer C, Huber H. Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 1992;13:893-901.
19. Sievers EL, Lange BJ, Buckley JD, Smith FO, Wells DA, Daigneault-Creech CA, Shults KE, Bernstein ID, Loken MR. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. J Natl Cancer Inst 1996;88:1483-1488.
20. Plata E, Choremi-Papadopoulou H, Viglis V, Yataganas X. Flow-cytometric detection of minimal residual disease with atypical antigen combinations in patients with de novo acute myeloid leukemia. Ann Hematol 2000;79:543-546.
21. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-1062.
22. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, Wheatley K, Burnett AK, Goldstone AH. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-1320.
23. Al-Mawali AH, To LB, D G, Hissaria P, Mundy J, Lewis ID. The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia. Int J Lab Hematol (in press). Doi: 10.1111/j.1751-553X.2007.01003.x.
24. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649.
25. Hosmer DW, Lemeshow S, editors. Applied Logistic Regression. New York:Wiley; 2000.
26. Bresters D, Reus AC, Veerman AJ, van Wering ER, van der Doesvan den Berg A, Kaspers GJ. Congenital leukaemia: The Dutch experience and review of the literature. Br J Haematol 2002;117: 513-524.
27. Chen W, Karandikar NJ, McKenna RW, Kroft SH. Stability of leukemia-associated immunophenotypes in precursor B-lymphoblastic leukemia/lymphoma: A single institution experience. Am J Clin Pathol 2007;127:39-46.
28. Kern W, Voskova D, Schnittger S, Schoch C, Hiddemann W, Haferlach T. Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia. Hematol J 2004;5:410-418.
29. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: Implications for residual disease detection: A report from the children's oncology group. Cytometry Part B Clin Cytom 2005;68B:18-24.
30. Digiuseppe JA. Acute lymphoblastic leukemia: Diagnosis and detection of minimal residual disease following therapy. Clin Lab Med 2007;27:533-549, vi.
31. Bastida Vila P, Palacio Garcia C, Solsona Riera M, Ortega Aramburu JJ, Sanchez de Toledo Codina J. [Minimal residual disease in acute lymphoblastic leukemia: A new concept of complete remission]. An Pediatr (Barc) 2005;63:390-395.
32. Sievers EL, Lange BJ, Alonzo TA, Gerbing RB, Bernstein ID, Smith FO, Arceci RJ, Woods WG, Loken MR. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: Results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia. Blood 2003;101:3398-3406.